PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
17.54
-0.46 (-2.58%)
Oct 16, 2025, 4:00 PM EDT - Market closed
PureTech Health Revenue
PureTech Health had revenue of $1.85M in the half year ending June 30, 2025, a decrease of -41.24%. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
$6.39M
Revenue Growth
+1,265.60%
P/S Ratio
67.75
Revenue / Employee
$114,125
Employees
56
Market Cap
432.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PRTC News
- 17 days ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 7 weeks ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 7 weeks ago - PureTech Health plc – Half-Year Report - Business Wire
- 2 months ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 2 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 2 months ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire
- 2 months ago - PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases - Business Wire
- 3 months ago - PureTech Announces Leadership Transition - Business Wire